MAY 3.1 2007 B

CERTIFICATE OF FIRST CLASS MAILING

I here Westify that this correspondence is being deposited with the United States Postal Service under 37 CFR §1.8 on the date indicated below and with sufficient postage addressed to Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

Printed Name Gary R. Fabian

Printed Name Guy R. Fabian

29 May 2007

Signature Date of Deposit

IN THE UNITED STATES PATI	ENT AND TRADEMARK OFFICE
In Re Application of: Stanford Mark Moran	Confirmation No. 8022
Serial No.: 10/004,118	Art Unit: 1647
Filing Date: 30 October 2001	Examiner: Seharaseyon, J.
Title: Previously "Method for short-term and lo METHOD FOR TREATING DISEASES	ng-term drug dosimetry," as currently amended WITH OMEGA INTERFERON

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The information listed below may be material to the examination of the above-identified application. A completed Form PTO-1449 and copies of the cited references accompany this paper.

Further, because this application was filed after 30 June 2003, copies of the cited U.S. Patent publication has not been submitted pursuant to the waiver described in pre-OG Notice "Information Disclosure Statements may be filed without copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.

Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record in the present application.

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to

Intarcia Ref. No. INT 004.10 USSN 10/004,118 PATENT

the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Authorization to Charge Deposit Account:

The Commissioner is hereby authorized to charge \$180.00 under 1.17(p) for Submission of an Information Disclosure Statement to Deposit Account No. 504212 (please reference docket number INT 004.10). No additional fees are believed due in connection with this paper. However, the Commissioner is hereby authorized to charge to Deposit Account No. 504212 (please reference docket number INT 004.10) any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

Respectfully submitted,

Date: 29 May 2007

By: Yay & Febrain Gary R. Fabian, Ph.D.

Agent for Applicants Registration No. 33,875

Intarcia Therapeutics, Inc. 2000 Powell Street Suite 1640 Emeryville, CA 94608



FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) Sheet _1_ of _1

In the Application of: Stanford Mark Moran

Serial No.: 10/004,118

Confirmation No.: 8022

Art Unit: 1647

Filed: 30 October 2001

Examiner: Seharaseyon, J.

Title: Previously "Method for short-term and long-term drug dosimetry," as currently amended -- METHOD FOR

TREATING DISEASES WITH OMEGA INTERFERON --

U.S. PATENT DOCUMENTS							
Exam. Init.	Ref. Desig.	Document No.	Date	Name	Class	Sub Class	Filing Date
	DA-01	6,875,748	April 5, 2005	Manthorpe, et al.			
	DA-						

FOREIGN PATENT DOCUMENTS								
Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class	Sub Class	Transl YES	ation NO
	DB-01	WO 00/40273A2	13 July 2000	WIPO/PCT				
	DB-02	WO 00/40273A3	13 July 2000	WIPO/PCT				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)					
Exam. Init.	Ref. Desig.	Description			
		·			
	DC-				
	}				
	DC-				

Examiner:	Date Considered:

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.